HilleVax is a startup based in the United States, most recent round Series B, 5 tracked investors.
Based in the United States, HilleVax is a startup. Its most recent tracked round is Series B. Brouky records 5 investors associated with the company.
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, with its initial program HIL-214 being a virus-like particle based vaccine candidate for preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.